AMPLITUDE-O (Cardiovascular and Renal Outcomes with Efpeglenatide in Type 2 Diabetes), on the other hand, is a trial in which weekly subcutaneous injections of efpeglenatide (4 or 6 mg) for a median of 1.8 years led to a 27% lower risk of incident MACEs and a 32% lower risk of a composite renal outcome event than placebo among persons with T2DM and either a history of CVD or current kidney disease [39]
Common effects include: Nausea or stomach upset Constipation or diarrhea Vomiting in rare cases Reduced appetite In most cases, these effects decrease after several weeks
The most common side effects are mild and include nausea, diarrhea, and fatigue
Ozempic as an add-on to basal insulin and Ozempic 1 mg vs 2 mg Primary endpoint: change in A1C from baseline SUSTAIN 5: add-on basal insulin 1,10,11 In adult patients with type 2 diabetes on basal insulin metformin Mean change in A1C from baseline at Week 30 Mean baseline A1C: SUSTAIN FORTE: Ozempic 1 mg vs 2 mg 1,8 In patients with type 2 diabetes on metformin sulfonylurea Mean change in A1C from baseline at Week 40 Mean baseline A1C: Results for SUSTAIN 5 and SUSTAIN FORTE based on sensitivity analyses of retrieved dropout population
It's about offering people control, clarity, and continuity in an era where so many health solutions feel fragmented or overwhelming
This includes healthcare fraud, DEA drug diversion (defending doctors and practitioners), wire and mail fraud, money laundering, SEC investigations, and RICO charges
